Detection of anti-human T-lymphotropic virus type I antibody in whole blood by a novel counting immunoassay.
نویسندگان
چکیده
BACKGROUND Assays to screen for and confirm the presence of the antibody for human T-lymphotropic virus type I (HTLV-I) are currently performed with serum or plasma. We developed and evaluated a new counting immunoassay (CIA) for the detection of HTLV-I antibody in whole blood, using recombinant and synthetic peptide antigens. METHODS We assessed the CIA for detection of HTLV-I antibody in whole blood and plasma. The CIA is an immunity-measuring method that combines latex agglutination with particle-counting technology. The numbers of agglutinated latex particles, single latex particles, and blood cells in a sample are measured based on differences in particle size between latex particles and blood cells. RESULTS The CIA and ELISA methods were in agreement for all 24 plasma samples tested, including those from 6 patients with HTLV-I-associated diseases, 6 HTLV-I carriers, and 12 HTLV-I antibody-negative individuals. The concordance between the ELISA (plasma) and the CIA (whole blood) for samples from 24 patients was 100%. The concordance between a particle agglutination method (plasma) and the CIA (plasma or whole blood) for 1065 patients was 99.5%. The concordance between results obtained for 1065 pairs of plasma and whole blood samples with the CIA method was 100%. HTLV-I antibody in whole blood was stable for 3 days after blood collection. With this CIA method, results were available within 15 min. CONCLUSIONS The CIA method can be used in screening for HTLV-I. The use of whole blood rather than serum or plasma reduces the sample volume and number of blood collections required, as well as assay time.
منابع مشابه
Evaluating the Frequency of Human T-Lymphotropic Virus Type 1 Infection in Iranian Population
Background: Human T-cell lymphotropic viruses 1 (HTLV1) is endemic in specific regions. We aimed to determine the prevalence of HTLV I infection among blood donors in southeast Iran. Methods: This cross-sectional study was conducted between April 2005 and March 2015. Sera were collected from blood donors and were tested for the presence of HTLV1 specific antibody using ELISA. Reactive sample...
متن کاملDetection of early human T-cell lymphotropic virus type I antibody patterns during seroconversion among transfusion recipients.
From a cohort of human T-cell lymphotropic virus type I (HTLV-I) exposed transfusion recipients (N = 71) enrolled in the Jamaican Transfusion Study, 11 were selected for detailed laboratory evaluation. All recipients were followed at monthly intervals for 6 months and then bimonthly up to 1 year for evidence of HTLV-I seroconversion. Without regard to results on screening assays, pretransfusion...
متن کاملThe Enigma of Human T-Cell Leukemia Virus Type-1 (HTLV-1) Infection in Iran
Human T-cell lymphotropic virus type-I (HTLV-I) was the first human retrovirus associated with malignancy. The prevalence of HTLV-I infection varies significantly in different regions of the world. In this study, the prevalence of HTLV-I infection among ethnic Jews living in Shiraz, South of Iran, was investigated. 286 blood samples were obtained. HTLV-1 antibody assay on serum samples was d...
متن کاملEvaluating the frequency of HTLV-Ι/Π infection among blood donors, major thalassemic patients and individuals infected with hepatitis B and C viruses in Isfahan, Iran
Background: The human T-cell lymphotropic virus type I is the first retrovirus idenfied in humans. The virus has been associated with adult T-cell leukemia/lymphoma, human T-lymphotropic virus type I, myelopathy/tropical spasc paraparesis, uveis, arthris, pulmonary lymphocyc alveolis, keratoconjuncvis sicca, and infecous dermas. Human T-lymphotropic virus type Iis endemic in Japan...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Clinical chemistry
دوره 49 2 شماره
صفحات -
تاریخ انتشار 2003